3.
Ministry of Health and Social Protection. Evidence-based clinical practice guidelines for HIV infection care of teenagers (13
years old and older) and adults. (2014).
4.
Mallal, S. et al. HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase. THE LANCET 359, 6 (2002).
5.
Hetherington, S. et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. The Lancet 359, 1121–1122 (2002).
6.
Hughes, C. A. et al. Abacavir Hypersensitivity Reaction: an Update. Ann. Pharmacother. 42, 387–396 (2008).
7.
Clay, P. G. The abacavir hypersensitivity reaction: A review. Clin. Ther. 24, 1502–1514 (2002).
8.
Hetherington, S. et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase
inhibitor abacavir. Clin. Ther. 23, 1603–1614 (2001).
9.
Cutrell. Updated clinical risk factor analysis of suspected hypersensitivity reactions
to abacavir. Ann. Pharmacother. 38, 2172–2173 (2004).
10.
Symonds, W. et al. Risk factor analysis of hypersensitivity reactions to abacavir. Clin. Ther. 24, 565–573 (2002).
11.
Easterbrook, P. et al. Epidemiological risk factors for hypersensitivity reactions to abacavir*. HIV Med. 4, 321–324 (2003).
12.
Araújo, C. de et al. Prevalence of Human Leukocyte Antigen HLA-B*5701 in HIV-1 Infected Individuals in
Brazil. Open J. Genet. 04, 56–62 (2014).
13.
Carolino, F. et al. Prevalence of abacavir-associated hypersensitivity syndrome and HLA-B*5701 allele
in a Portuguese HIV-positive population: Porto Biomed. J. 2, 59–62 (2017).
14.
Mallal, S. et al. HLA-B*5701 Screening for Hypersensitivity to Abacavir. N Engl J Med 12 (2008). doi:10.1056/NEJMoa0706135
15.
Rauch, A. et al. Prospective Genetic Screening Decreases the Incidence of Abacavir Hypersensitivity
Reactions in the Western Australian HIV Cohort Study. Clin. Infect. Dis. 43, 99–102 (2006).
16.
Zucman, D., Truchis, P. de, Majerholc, C., Stegman, S. & Caillat-Zucman, S. Prospective
Screening for Human Leukocyte Antigen-B*5701 Avoids Abacavir Hypersensitivity Reaction
in the Ethnically Mixed French HIV Population: JAIDS J. Acquir. Immune Defic. Syndr. 45, 1–3 (2007).
17.
Waters. Prospective HLA-B5701 screening and ABC hypersensitivity, a single centre
experience. (2007).
18.
Sun, H.-Y. et al. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected
patients in Taiwan. J. Antimicrob. Chemother. 60, 599–604 (2007).
19.
Orkin, C. et al. An epidemiologic study to determine the prevalence of the HLA-B*5701 allele among
HIV-positive patients in Europe: Pharmacogenet. Genomics 20, 307–314 (2010).
20.
Guo, Y. et al. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation
of pharmacogenetics to personalized medicine. Sci. China Life Sci. 56, 119–124 (2013).
21.
Small, C. B., Margolis, D. A., Shaefer, M. S. & Ross, L. L. HLA-B*57:01 allele prevalence
in HIV-infected North American subjects and the impact of allele testing on the incidence
of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects.
BMC Infect. Dis. 17, (2017).
22.
Baniasadi. Prevalence of HLA-B*5701 and Its Relationship with Abacavir Hypersensitivity
Reaction in Iranian HIV- Infected Patients. 5 (2016).
23.
Poggi, H. et al. HLA-B*5701 frequency n Chilean HIV-infected patients and in general population. Braz. J. Infect. Dis. 14, 510–512 (2010).
24.
Sanchez-Giron, F. et al. Association of the genetic marker for abacavir hypersensitivity HLA-B*5701 with HCP5 rs2395029 in Mexican Mestizos. Pharmacogenomics 12, 809–814 (2011).
25.
Arrieta-Bolaños, E., Madrigal, J. A., Marsh, S. G. E., Shaw, B. E. & Salazar-Sánchez,
L. The frequency of HLA-B∗57:01 and the risk of abacavir hypersensitivity reactions in the majority population
of Costa Rica. Hum. Immunol. 75, 1092–1096 (2014).
26.
Crovella, S. et al. Frequency of HLA B*5701 allele carriers in abacavir treated-HIV infected patients
and controls from northeastern Brazil. Clinics 66, 1485–1488 (2011).
27.
Moragas, M. et al. Prevalence of HLA-B*57:01 allele in Argentinean HIV-1 infected patients: HLA-B*57:01
in HIV-1 infected patients. Tissue Antigens 86, 28–31 (2015).
30.
Martin, A. M., Nolan, D. & Mallal, S. HLA-B*5701 typing by sequence-specific amplification:
validation and comparison with sequence-based typing. Tissue Antigens 65, 571–574 (2005).
31.
Phillips, E. J. Genetic Screening to Prevent Abacavir Hypersensitivity Reaction: Are
We There Yet? 3 (2006).
32.
Phillips, E. & Mallal, S. Successful translation of pharmacogenetics into the clinic:
the abacavir example. Mol. Diagn. Ther. 13, 1–9 (2009).
33.
Suarez-Kurtz, G. & J. Pena, S. Pharmacogenomics in the Americas: The Impact of Genetic
Admixture. Curr. Drug Targets 7, 1649–1658 (2006).
34.
Martin, M. A. et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype
and Abacavir Dosing. Clin. Pharmacol. Ther. 91, 734–738 (2012).